The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care

Matsuzaki, Yuichi; Kelly, John; Shoji, Tetsuo; Shinoka, Toshiharu

doi:10.3390/app9071274

Cited by 108 publications

(93 citation statements)

References 68 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After implantation, the tissue-engineered vascular graft (TEVG) is replaced by the host's cells and ECM and is thereby degraded [4]. However, the loss of mechanical properties due to a too rapid degradation and unfavorable biological reactions to the degradation products remain a major challenge [1,53]. A recent study addressed this problem by producing a TEGV that consists of a combination of a biodegradable and biostable polymer [54].…”

Section: Introductionmentioning

confidence: 99%

Fibronectin Adsorption on Electrospun Synthetic Vascular Grafts Attracts Endothelial Progenitor Cells and Promotes Endothelialization in Dynamic In Vitro Culture

Daum

Visser

Wild

et al. 2020

Cells

View full text Add to dashboard Cite

Appropriate mechanical properties and fast endothelialization of synthetic grafts are key to ensure long-term functionality of implants. We used a newly developed biostable polyurethane elastomer (TPCU) to engineer electrospun vascular scaffolds with promising mechanical properties (E-modulus: 4.8 ± 0.6 MPa, burst pressure: 3326 ± 78 mmHg), which were biofunctionalized with fibronectin (FN) and decorin (DCN). Neither uncoated nor biofunctionalized TPCU scaffolds induced major adverse immune responses except for minor signs of polymorph nuclear cell activation. The in vivo endothelial progenitor cell homing potential of the biofunctionalized scaffolds was simulated in vitro by attracting endothelial colony-forming cells (ECFCs). Although DCN coating did attract ECFCs in combination with FN (FN + DCN), DCN-coated TPCU scaffolds showed a cell-repellent effect in the absence of FN. In a tissue-engineering approach, the electrospun and biofunctionalized tubular grafts were cultured with primary-isolated vascular endothelial cells in a custom-made bioreactor under dynamic conditions with the aim to engineer an advanced therapy medicinal product. Both FN and FN + DCN functionalization supported the formation of a confluent and functional endothelial layer.

show abstract

Section: Introductionmentioning

confidence: 99%

Fibronectin Adsorption on Electrospun Synthetic Vascular Grafts Attracts Endothelial Progenitor Cells and Promotes Endothelialization in Dynamic In Vitro Culture

Daum

Visser

Wild

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Although tissue-engineered grafts convert into mature vessels through inflammation-mediated remodeling (Roh et al, 2010), they worsen due to thrombosis, intimal hyperplasia, and restenosis caused by uncontrolled chronic inflammation. Optimizing scaffolds to improve the prospects of current tissue engineered vascular graft technologies will advance the field of cardiovascular surgery (Matsuzaki et al, 2019).…”

Section: Devices In the Arterial Systemmentioning

confidence: 99%

Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices

Labarrere

Dabiri

Kassab

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Blood-contacting medical devices of different biomaterials are often used to treat various cardiovascular diseases. Thrombus formation is a common cause of failure of cardiovascular devices. Currently, there are no clinically available biomaterials that can totally inhibit thrombosis under the more challenging environments (e.g., low flow in the venous system). Although some biomaterials reduce protein adsorption or cell adhesion, the issue of biomaterial associated with thrombosis and inflammation still exists. To better understand how to develop more thrombosis-resistant medical devices, it is essential to understand the biology and mechano-transduction of thrombus nucleation and progression. In this review, we will compare the mechanisms of thrombus development and progression in the arterial and venous systems. We will address various aspects of thrombosis, starting with biology of thrombosis, mathematical modeling to integrate the mechanism of thrombosis, and thrombus formation on medical devices. Prevention of these problems requires a multifaceted approach that involves more effective and safer thrombolytic agents but more importantly the development of novel thrombosis-resistant biomaterials mimicking the biological characteristics of the endothelium and extracellular matrix tissues that also ameliorate the development and the progression of chronic inflammation as part of the processes associated with the detrimental generation of late thrombosis and neo-atherosclerosis. Until such developments occur, engineers and clinicians must work together to develop devices that require minimal anticoagulants and thrombolytics to mitigate thrombosis and inflammation without causing serious bleeding side effects.

show abstract

“…Furthermore, functionalization of TEVGs with biological signals such as the angiogenic cytokine VEGF have been shown to trigger in situ tissue endothelial regeneration (Koobatian et al, 2016). Although advances in traditional translational approaches for cardiac anomalies have paved the way for regenerative medicine, these TEVGs still suffer from a number of common issues including insufficient patency, integration, hemodynamics, immune-compatibility with the graft cell source and mechanical strength, as outlined by others (Pashneh-Tala et al, 2016;Matsuzaki et al, 2019;Skovrind et al, 2019).…”

Section: Regenerative Medicinementioning

confidence: 99%

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

Davaapil

Shetty

Sinha

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Thoracic aortic diseases, whether sporadic or due to a genetic disorder such as Marfan syndrome, lack effective medical therapies, with limited translation of treatments that are highly successful in mouse models into the clinic. Patient-derived induced pluripotent stem cells (iPSCs) offer the opportunity to establish new human models of aortic diseases. Here we review the power and potential of these systems to identify cellular and molecular mechanisms underlying disease and discuss recent advances, such as gene editing, and smooth muscle cell embryonic lineage. In particular, we discuss the practical aspects of vascular smooth muscle cell derivation and characterization, and provide our personal insights into the challenges and limitations of this approach. Future applications, such as genotype-phenotype association, drug screening, and precision medicine are discussed. We propose that iPSC-derived aortic disease models could guide future clinical trials via "clinical-trials-in-a-dish", thus paving the way for new and improved therapies for patients.

show abstract

The Evolution of Tissue Engineered Vascular Graft Technologies: From Preclinical Trials to Advancing Patient Care

Cited by 108 publications

References 68 publications

Fibronectin Adsorption on Electrospun Synthetic Vascular Grafts Attracts Endothelial Progenitor Cells and Promotes Endothelialization in Dynamic In Vitro Culture

Fibronectin Adsorption on Electrospun Synthetic Vascular Grafts Attracts Endothelial Progenitor Cells and Promotes Endothelialization in Dynamic In Vitro Culture

Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

Contact Info

Product

Resources

About